CRDL 6-K SEC Filing Analysis

Latest settled — T+5d

CRDL ▼ -6.15% at T+5d

NEUTRAL call ✗ call lost -6.15% · α vs SPY -7.24% · entry $1.30 → $1.22

Next anchor: T+20d in 14d

Last close $1.08 (close Jun 8) · -16.92% from $1.30 entry

Entry anchored
May 22, 03:59 PM ET
via Databento tick

T+1d

-1.54%

call -1.54% · α -1.55%

$1.28

settled 14d ago

T+5d

-6.15%

call -6.15% · α -7.24%

$1.22

settled 8d ago

T+20d

—

call — · α —

—

in 14d

T+60d

—

call — · α —

—

in 2mo

Price Chart

Loading chart...

Executive Summary

Cardiol Therapeutics filed its management information circular and notice of annual general meeting for June 24, 2026. The filing is a routine proxy solicitation with standard items: election of eight directors, appointment of BDO Canada LLP as auditors, and receipt of audited financial statements. No material financial data, business developments, or strategic changes are disclosed.

Actionable Insight

This is a routine annual meeting proxy filing with no trading implications. Monitor for any subsequent 6-K filings that may contain clinical trial updates or financial results, which would be the primary catalysts for this clinical-stage biotech.

Key Facts

Annual general meeting scheduled for June 24, 2026, at 4:30 p.m. EDT, held virtually.
Board proposes election of eight director nominees: David Elsley, Peter Pekos, Dr. Guillermo Torre-Amione, Colin Stott, Jennifer Chao, Christopher Waddick, Teri Loxam, and Dr. Timothy Garnett.
Appointment of BDO Canada LLP as auditors for fiscal year ending December 31, 2026, with remuneration to be fixed by the Board.
As of May 7, 2026 record date, 115,272,240 Class A common shares were issued and outstanding.
MM Asset Management Inc. holds 15,352,317 shares (13.3%) and warrants for an additional 5,711,539 shares (17.4% partially diluted).
No material financial results, guidance, or business updates are included in the filing.

Financial Impact

No financial impact — routine proxy filing with no new financial data or material events.

Risk Factors

No material risks disclosed beyond standard corporate governance matters.

Market Snapshot

Exchange

Nasdaq

Sector

Biological Products, (No Diagnostic Substances)

Analyst Consensus

89% bullish (9 analysts)

Documents Analyzed

This report is based on 8 SEC documents filed with EDGAR.

Document	Accession Number
6-K Filing (Primary)	0001104659-26-066043
Document: tm2615378d1_ex99-1.htm	0001104659-26-066043
Document: tm2615378d1_6k.htm	0001104659-26-066043
Document: tm2615378d1_ex99-3.htm	0001104659-26-066043
Document: tm2615378d1_ex99-4.htm	0001104659-26-066043
Document: 0001104659-26-066043-index-headers.html	0001104659-26-066043
Document: 0001104659-26-066043-index.html	0001104659-26-066043
Document: 0001104659-26-066043.txt	0001104659-26-066043

7 reports for CRDL

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for CRDL — sortable, filterable
	Type				Now
May 26, 2026 14d ago	6-K NEUTRAL ★ 2/10	$1.30 $1.22	▼ −6.15%	▼ −7.24%	$1.08 (−16.92%)
May 14, 2026 26d ago	6-K NEUTRAL ★ 2/10	$1.37 $1.31	▼ −4.38%	▼ −3.66%	$1.08 (−21.17%)
May 11, 2026 29d ago	6-K NEUTRAL ★ 5/10	$1.35 $1.28	▼ −5.19%	▼ −5.26%	$1.08 (−20.00%)
May 7, 2026 4w ago	6-K BULLISH ★ 6/10	$1.30 $1.36	▲ +4.62%	▲ +3.11%	$1.08 (−16.92%)
Apr 14, 2026 8w ago	6-K NEUTRAL ★ 3/10	$1.40 $1.63	▲ +16.43%	▲ +15.03%	$1.08 (−22.86%)
Apr 10, 2026 8w ago	6-K NEUTRAL ★ 2/10	$1.38 $1.51	▲ +9.42%	▲ +4.92%	$1.08 (−21.74%)
Apr 1, 2026 9w ago	6-K BULLISH ★ 8/10	$1.40 $1.38	▼ −1.43%	▼ −5.19%	$1.08 (−22.86%)

US Market Status

Market Closed — Opens in 6h 46m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access